Clinical analysis for pregnancy outcome of previous TORCH infection patients evolved with in vitro fertilization/intracytoplasmic sperm injection-embryo transfer
10.3760/cma.j.cn101441-20201010-00551
- VernacularTitle:既往TORCH感染对IVF/ICSI-ET妊娠结局影响的临床分析
- Author:
Zheng LIU
1
;
Sanhua WEI
1
;
Xiaohong WANG
1
Author Information
1. 中国人民解放军空军军医大学第二附属医院妇产科生殖医学中心，西安 710038
- Publication Type:Journal Article
- Keywords:
Fertilization, in vitro;
Sperm injection, intracytoplasmic;
Embryo transfer;
Pregnancy outcome;
TORCH;
Previous infection
- From:
Chinese Journal of Reproduction and Contraception
2022;42(5):503-508
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the influence of previous TORCH infection on pregnancy outcome of in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET). Methods:A retrospective cohort study was carried out for infertile female patients who underwent IVF/ICSI-ET treatment from May 2016 to May 2018 at Department of Obstetrics and Gynecology, Reproductive Medicine Center, the Second Affiliated Hospital, Air Force Military Medical University. IgM and IgG in serum have been detected for cytomegalovirus (CMV), herpes simplex virus (HSV), rubella virus (RV) and Toxoplasma (TOX) by enzyme-linked immunosorbent assay (ELISA). Patients with IgM negative and IgG positive [IgM(-), IgG(+)] were assigned as the previous infection,while IgM-negative and IgG-negative [IgM(-), IgG(-)] were assigned as negative control. Four groups of CMV [1984 IgG(+) cases vs. 421 IgG(-) cases], HSV [1535 IgG(+) cases vs. 344 IgG(-) cases], RV [1795 IgG(+) cases vs. 261 IgG(-) cases] and TOX [75 IgG(+) cases vs. 2111 IgG(-) cases] were investigated for general data and pregnancy outcome of IVF/ICSI-ET. Results:There were no significant differences between previous infection and negative control at age, body mass index (BMI), infertility duration, basal follicle-stimulating hormone (FSH) and anti-Müllerian hormone (AMH) levels among four groups (all P>0.05). The number of oocytes retrieved (9.68±4.33, 10.04±3.99, 10.41±4.33), fertilization rate [82.01% (1627/1984), 82.74% (1270/1535), 82.95% (1489/1795)], clinical pregnancy rate [53.20% (1055/1984), 51.66% (793/1535), 52.98% (951/1795)] and live birth rate [50.25% (997/1984), 38.96% (598/1535), 40.33% (724/1795)] in CMV, HSV, and RV IgG positive groups were significantly lower than those in the negative control [10.18±4.41, 10.58±3.54, 11.08±3.90, P=0.032, P=0.021, P=0.018; 86.46% (364/421), 87.21% (300/344), 88.12% (230/261), P=0.028, P=0.043, P=0.035; 58.4% (246/421), 58.14% (200/344), 60.54% (158/261), P=0.049, P=0.030, P=0.022; 55.58% (234/421), 46.51% (160/344), 47.89% (125/261), P=0.047, P=0.010, P=0.021]. However, the biochemical pregnancy rate [9.47% (188/1984), 9.12% (140/1535), 10.53% (189/1795)] and the miscarriage rate [10.48% (208/1984), 9.97% (153/1535), 10.97% (197/1795)] in CMV, HSV, and RV IgG positive groups were higher than those in the negative group [6.18% (26/421), 5.81% (20/344), 6.51% (17/261), P=0.031, P=0.047, P=0.044; 7.13% (30/421), 6.10% (21/344), 6.51% (17/261), P=0.036, P=0.026, P=0.027]. There were no significant differences in the number of oocyte retrieved, fertilization rate, clinical pregnancy rate and live birth rate between the TOX IgG positive group and the negative control (all P>0.05). Conclusion:Previous infections of CMV, HSV and RV may be the reason for the fewer number of oocyte retrived and lower fertilization rate, clinical pregnancy rate and live birth rate for patients undergoing IVF/ICSI-ET treatment. Previous infections of CMV, HSV and RV cause the higher biochemical pregnancy rate and miscarriage rate. The previous TOX infection has no infection on IVF/ICSI-ET pregnancy outcome.
